12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Deals

Ember Therapeutics, Brigham and Women's Hospital, Dana-Farber Cancer Institute deal

Ember received exclusive options to IP for three targets related to its brown fat small molecule drug discovery program. Brigham and Women's Hospital gave the company an option for IP surrounding aldehyde dehydrogenase 1 family member A1...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >